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Abstract
Background: Chronic foot ulcers in diabetes are serious, costly and frequently difficult to heal. Recent guidelines
conclude that new dressings and treatments generally fail to show superiority compared with standard of care.
Several mechanisms are probably responsible for impaired healing of chronic foot ulcers, including inflammation
and infection. Chloramines have presumed antiseptic and antibacterial properties, and have shown to be a useful
treatment in odontology.
Methods: In an explorative open randomised controlled multi-centre study, we compared chloramine-based
treatment with current standard of care for 12 weeks and follow-up for 24 weeks. Seventeen patients in each
group, mean age about 70, duration of diabetes > 20 years and foot ulcers about 1.5 years, completed the 12
weeks study.
Results: After 5 weeks, the difference between the groups in relative reduction in ulcer area was statistically
significant (p=0.016). Absolute change in ulcer area was first statistically significant within the chloraminetreated
group after 2 weeks (p=0.026), after 8 weeks in the control group (p=0.0023), with significant difference between
groups after 5 weeks (p=0.024). The approximate relative decrease per week was 19.4% (95%CI 12.2, 26.0; p<0.0001)
in the chloramine-treated group and 11.7% (95%CI 6.4, 16.7; p<0.0001; between-group difference p=0.083). After 9
weeks 7 patients had healed in the chloraminetreated group, but only one in the control group (p=0.039). There
were no statistically significant differences in wound healing at 12 or 24 weeks, and no marked differences in signs
of infection, pain, quality of life (EQ-5D), or incidence of adverse events.
Conclusions: Chloramine-based treatment seems to be efficacious, particularly in the early phase of the care of
infected diabetic foot ulcers. It is safe and easy to use, and could prove to be a valuable addition in the treatment
arsenal, providing non-surgical debridement. Future studies will evaluate its role in wound care.
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Background
Non-healing foot ulcer is a serious and costly complication
of diabetes mellitus [1]. The pathophysiology is multifactor-
ial, including neuropathy, microvascular and macrovascular
angiopathy, foot deformities, impaired wound healing and
infections [2]. Thus, management of diabetes foot ulcers
has to include multiple modalities, such as effective offload-
ing, improvement of circulation, wound bed preparation
and removal of dead tissue, and treatment of infection.
However, with few exceptions, new treatment options have
usually failed to show superior effectiveness compared with
modern standards of care [3, 4].
Several mechanisms are probably responsible for
impaired healing of chronic foot ulcers, such as an inflam-
matory state, including ineffective neoangiogenesis, fibro-
blast infiltration, granulation, and re-epithelialization [5].
Bacteria colonizing diabetic foot ulcers in complex
biofilms have also been suggested to contribute to its
treatment-resistant state [5–8]. Organic chloramines have
multiple effects, which could be beneficial in wound care.
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They have presumed antiseptic and antibacterial proper-
ties [9, 10], and have also been shown to degrade toxins
and biofilms [11, 12]. In odontology chloramines facilitate
effective chemo-mechanical cleansing and debridement
while preserving healthy tissue [13–16].
The aim of this study was to assess whether a chlor-
amine preparation can be used in conjunction with
weekly dressings to improve healing of diabetic foot ul-
cers. A product used for periodontitis (Perisolv™, RLS
Global AB, Gothenburg, Sweden) was modified and used
in an explorative open randomized and controlled study,
compared with current standard treatment.
Methods
Patients and baseline characteristics
The Ethics Review Board of the University of Gothenburg
and the Swedish Medical Products Agency approved this
study. We recruited and treated 39 patients with diabetes
and foot ulcers at four centres in the Gothenburg area.
The patients were randomized in blocks of four to stand-
ard treatment or treatment with chloramine.
We used these inclusion criteria: type 1 or type 2 dia-
betes, age 18 years or older, and an infected foot ulcer for
more than 4 weeks. The presence of infection was defined
as two or more markers of inflammation (local warmth,
erythema, local swelling or induration around the ulcer,
local tenderness or pain), purulent discharge, i.e. mild or
moderate infection, as defined by the Infectious Diseases
Society of America [17]. Initially a minimum ulcer size of
300 mm2 was required, but after 10 months the minimal
ulcer size was changed to 25 mm2 due to slow recruitment
(after a survey evaluating ulcer size in 60 consecutive pa-
tients, followed by formal approvals). We excluded patients
with end-stage renal disease, impaired blood circulation
(toe arterial blood pressure < 30 mmHg, measured accord-
ing to Johansson et al. [18], or in need of vascular interven-
tion, or a vascular intervention performed less than three
months before the study, a history of kidney or pancreas
transplant, treatment with cortisone at higher doses than
60 mg daily, chemotherapy or any immune-modulating
agents during the past year, other identified conditions in
the area of the ulcer (e.g. cancer), or generally poor condi-
tion at risk of requiring hospitalisation. Although previous
use of biological dressings was not an exclusion criterion,
no patients were previously treated with this modality. We
also did not include patients with a severe infection (poor
general condition or metabolic disorders).
At the screening appointment, the following charac-
teristics were documented: age, sex, type and duration
of diabetes, of diabetes, history of myocardial infarc-
tion or stroke, HbA1c, duration and position of the
ulcer. The area of the ulcer was calculated (rectangu-
lar: length × width; circular: radius × radius × pi (3.14);
triangular: base × height/2). Sensory neuropathy was
determined using a tuning fork (128 Hz).
Treatments
Nurses and podiatrists performed cleansing and debride-
ment of the ulcers in both groups at least once weekly
for 12 weeks, but were treated (if needed) and followed
for 24 weeks. In patients randomized to chloramine
treatment, we applied a preparation containing sodium
hypochlorite and amino acids, which are converted to
chloramines by mixing the two components immediately
prior to the treatment [19]. The formed chloramines are
mild oxidising agents, which can transfer chlorine to
other substrates, regenerating the parent amine in the
process [20]. The gel was applied on the ulcer during
treatment sessions once a week. Debridement was per-
formed without sharp instruments, with the gel left on
the ulcer surface to give antibacterial protection for the
exposed tissue. This procedure lasted five minutes and
was done twice. The ulcer was then rinsed with water,
leaving no substance that could interfere with healing.
Finally, the ulcer was dressed with a non-adhesive pro-
tective dressing and self-adhesive fabric. If needed, a
new dressing could be applied between the weekly
appointments.
In the patients randomized to standard treatment, the
ulcer was cleansed and debrided according to guidelines
presented by International Working Group of Diabetic
Foot once weekly (or more often if needed) [21]. The
ulcer was dressed with foam, hydrocolloid or alginate
dressings, keeping a moist wound environment. In a few
cases an adjusted antiseptic agent, silver or PHMB, was
also used.
A photo was taken every week after the treatment,
with a ruler (millimetres) in the photo with the patient
ID number and date. The area of the ulcer was subse-
quently measured from the photos by an independent
and blinded observer. We also evaluated pain (visual-
analogue scale) and quality of life (EQ-5D).
All patients were given standard of care advice con-
cerning the treatment of diabetes and risk factors. Oral
antibiotic treatment was offered in situations with signs
of significant infection, particularly affecting underlying
tissue or bone. Appropriate off-loading was considered
and emphasized in all patients, i.e. individually tested
orthopaedic shoes and inserts, use of removable cast
walker boots (e.g., Aircast) or even wheelchairs. If
needed, patients were referred for peripheral vascular
examinations or intervention.
Statistical analyses
Ulcer sizes were measured once weekly for 12 weeks,
and a final evaluation was carried out after 24 weeks to
document the status of the ulcer (healed or not), time to
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healing and occurrence of adverse effects. In order to
detect a difference of 300 mm2 in the primary efficacy
variable (absolute change in area of the ulcers from the
baseline visit to week 12 between the chloramine treat-
ment group and the standard treatment group with two-
sided t-test with a power of 90 % and significance level
of 0.05 %) at least 18 patients were needed in each
group. We assumed equal standard deviation (SD) of
266 mm2 in both groups. In a comparable study the SD
was estimated to 267 mm2 in the active group and
86 mm2 in the control group [22]. In order to adjust for
loss to follow-up and early discontinuation, 20 patients
in each group, 40 in total, needed to be randomized.
For descriptive purposes, means, standard deviations
(SD), medians, minimum and maximum values are given
for continuous variables and number and percentages
for categorical variables. Non-parametric statistical
methods were used for all main analyses. Due to the
relative small samples non-parametric permutation tests
were used to achieve maximum power. For comparison
of both efficacy variables and baseline variables between
the two groups, Fisher’s non-parametric permutation
test was used for continuous variables, Fisher’s exact test
for dichotomous variables, Mantel-Haenszel chi-square
test for ordered categorical variables and chi-square test
for non-ordered categorical variables. Last observation
carried forward was applied to all missing primary and
secondary efficacy variables data after the baseline, but
baseline values were not carried forward. Time to heal-
ing were described with Kaplan-Meier curves and ana-
lysed unadjusted with log-rank test and adjusted with a
Cox proportional hazard regression model.
All efficacy analyses were performed on both the
intention-to-treat (ITT) population and the per protocol
(PP) population. All ITT analyses were based on as-
randomized treatment groups. All PP and safety analyses
were based on as-treated (actual) treatment groups. PP
results are presented in the results section.
All tests were two-tailed and conducted at 5 % sig-




In all, 40 patients were randomised, 21 to chloramines
treatment and 19 to standard care. In the chloramine-
treated group, one patient was excluded because he had
not reported a recent percutaneous angioplasty, one
who made irregular contact and was included in the
study at two centres, one because two ulcers coalesced
and were not possible to evaluate, and one who missed 6
appointments. One patient was erroneously included in
spite of a lower toe blood pressure than 30 mmHg. This
violation of the protocol was accepted due to difficulties
to measure adequately, since the first toe had recently
undergone surgery, and clinically estimated adequate cir-
culation in area of the ulcer, which was not located on
the first toe. In the control group, one patient was lost
to follow-up after the baseline visit, while one chose to
withdraw informed consent. Thus, 17 patients in each
group completed the 12 weeks study. Only one patient
in each group used a wheelchair (apart from individually
tested orthopaedic shoes and inserts), and one patient in
each group used so-called Aircasts during parts of the
follow-up period.
Baseline characteristics
The mean ages (and SD, standard deviations) of the partici-
pants were 67.5 (SD11.8) and 74.5 (SD 12.3) years in the
patients randomized to chloramine treatment and the con-
trol group, respectively, with duration of diabetes of more
than 20 years (Table 1). The majority were male, non-
smoking, with overweight and unsatisfactory glycaemic and
blood pressure control, but with generally high physical ac-
tivity. Most of the participants exhibited sensory neur-
opathy while retinopathy, as well as a history of coronary
heart disease, was present in almost half of the patients.
More than half of the patients had had amputation of a
foot or one leg, and the majority had a history of foot
ulcer. The mean durations of the current ulcers were 1.78
(SD 3.26) and 1.19 (SD 1.69) years, respectively, and the
mean ulcer area was 542 (SD 927) mm2 in patients ran-
domized to chloramine treatment and 428 (SD 713) mm2
in the control group. There were no statistically significant
differences between the groups in any of the baseline
characteristics, and a sensitivity analysis (linear regression)
showed that the distribution of characteristics between
the groups was not skewed.
Changes in ulcer size
Figure 1 shows the change in ulcer area in the two treat-
ment groups relative to the baseline value. In the group
treated with chloramine, there was a significant reduc-
tion in ulcer size after three weeks and after six weeks in
the control group. At week five, the relative reduction in
ulcer area was statistically significant (p = 0.016) between
the groups. The absolute change in ulcer area was first
statistically significant in the chloramine-treated group
after two weeks (p = 0.026) and after eight weeks in the
control group (p = 0.0023), with a statistically significant
difference between the groups after five weeks (p = 0.024).
There was no significant difference between the groups in
the primary efficacy variable (absolute change in area of
the ulcers from the baseline visit to week 12).
Figure 2 gives the relative changes in ulcer area as a
function of time. The approximate relative decrease per
week was 19.4 % (95 % CI 12.2, 26.0; p <0.0001) in the
chloramine-treated group and 11.7 % (95 % CI 6.4, 16.7;
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p < 0.0001). This difference in relative decrease between the
groups did not reach statistical significance (p = 0.083).
Time to healing
During the early phase of the trial, the number of healed
ulcers was numerically higher in the chloramine-treated
group (Fig. 3). After nine weeks seven patients had
healed in the that group, but only one in the control
group producing statistical significance (comparison be-
tween groups p = 0.039). After 12 weeks two more ulcers
had healed in the control group, producing a statistically
non-significant difference between the groups. After
24 weeks 10 of the ulcers had healed in the chloramine
group and nine in the control group. Figure 3 gives
probability of being healed during the course of the full
24 weeks follow-up period.
Infection, pain, EQ-5D, and modelling
There were only minimal and non-significant changes in
HbA1c and CRP during the study. Signs of infection
were similar in the two groups throughout the follow-up
period. At the baseline visit, signs of infection were
present in 13 and 15 of the chloramine and the control
groups, respectively, while after 12 weeks 4 and 8 ulcers,
respectively, showed such signs. Although there were
statistically significant reductions within the groups dur-
ing the follow-up period, there were no significant differ-
ences between the groups. The use of antibiotic
treatment was more than 50 % during the 12 weeks
follow-up period (not statistically different between the
two groups). Pain measured with a visual-analogue scale
had improved significantly after 10 weeks in both groups
(no difference in pain in the groups). EQ-5D did not
show a significant improvement until the 24 weeks visit
in the chloramine group (no statistically significant dif-
ference between the groups).
There was large heterogeneity in ulcer sizes at base-
line, but a sensitivity analysis (linear regression), with all
baseline characteristics, including size and location of
the ulcer, toe blood pressure, number of follow-up visits
or variability in number of days between visits, revealed
that none of these variables was shown to affect the de-
crease in ulcer area during the study (all p–values
>0.05).
Safety
In the chloramine-treated group, the number of pre-
specified adverse events was 7 patients with increased
pain, 4 with non-study related injuries, and 2 with 50 %
increase in wound size (a few patients had more than
one adverse event). In the control group, 5 patients ex-
perienced increased pain, 3 had non-study related injur-
ies (6 injuries in total), and 2 had 50 % increase in
wound size.
There was also 1 fracture in each group (not study-
related). In the chloramine-treated group, 5 patients re-
quired a vascular procedure or an amputation of a toe
(in 1 case 10 days after the baseline visit due to tight su-
tures after surgery prior to study start, and the other one
after 17 weeks). In the control group, 3 patients required
a vascular procedure, one of whom had a lower leg am-
putation (on the side of the foot ulcer) after 17 weeks.
Discussion
This explorative open randomized controlled trial shows
that chloramine can safely be used in the treatment of
infected foot ulcers in diabetes. The absolute and relative
ulcer area improved, time to healing was shorter, and
the number of healed foot ulcers was increased in pa-
tients randomised to chloramine treatment during the
first two months of the study. These differences,
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including the primary outcome (absolute change in area
of the ulcers from the baseline visit to week 12), were
not, however, statistically significant after 12 and
24 weeks, suggesting that the efficaciousness of
chloramine-based weekly treatment is predominantly in
the early phases of ulcer treatment.
Wound healing has several phases, including haemo-
stasis, inflammation, proliferation and granulation, and
remodelling, eventually closing the wound. Patients with
diabetes mellitus often show impaired function of the
local immune system, and chronic ulcers could stall in
the inflammatory phase [23]. The patients participating
in this trial were around 70 years of age, with diabetes dur-
ation of more than 20 years, a history of micro- and
macrovascular complications, and exhibited unsatisfactory
risk factor control. The long duration of the ulcers of the
patients in the study (mean around 1.5 years), clearly illus-
trates the multifactorial nature of foot ulcers in diabetes
Fig. 2 Relative change in wound area as function of time
Fig. 1 Relative change in ulcer area (%) per treatment group and visit
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and the difficulties involved in developing methods and
improving wound care results [3].
Chloramines are not cytotoxic and have several prop-
erties, which could prove useful in the treatment of in-
fected wounds and ulcers, and thus might have
contributed to the beneficial effects in this trial [10, 24].
Subjectively, we had the impression of a more rapid
transformation from black or yellow necrosis in the ul-
cers to purulence and red granulation than in the con-
trol group. After reaching this phase, the ulcer healing
seemed to be similar in the two treatment groups. The
ulcers also appeared more easily debrided without dam-
aging the underlying tissue.
This study is limited by its open design, exploratory
nature and limited size, as well as the use of different
dressings required by the current status of the ulcers.
Differences in off-loading might also have been a limita-
tion, but use of a wheelchair was only used in one case
in each group, and only one patient in each group used
a removable cast walker boot temporarily. Wound care
is a dynamic process, requiring appropriate handling and
dressings at different stages. The non-adhesive protect-
ive dressing used in the chloramine-treated group might
have been advantageous in the first phases but a disad-
vantage later in the healing process. The active dressing
to keep a moist environment might similarly have been
a disadvantage in the early treatment of the control
group but an advantage later on. Furthermore, the
methods used to characterize the ulcers could be im-
proved, determining also ulcer volume and in more de-
tail the current stage in the healing process. The groups,
however, shared the same clinical characteristics, and
attended clinics and were cared for by experienced podi-
atrists, nurses and physicians. The indicator was current
standard of care, including even more frequent visits
than usually offered, suggesting that a treatment regimen
based on use of chloramine could represent an import-
ant addition to wound care.
Conclusions
Chloramine-based treatment seems to be efficacious,
particularly in the early phase of the care of infected dia-
betic foot ulcers. It is safe and easy to use, and could
prove to be a valuable addition in the treatment arsenal,
providing non-surgical debridement. The results of this
exploratory study will provide the basis for adequately
dimensioned forthcoming studies addressing the effects
in the healing of wounds and ulcers, not only in patients
with diabetes. Mechanistic studies are also needed to
study the effects in practice on infection, biofilm, local
immune response and the wound-healing cascade.
Fig. 3 Time to healing
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